Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 8, 2007, Pages 541-545

  Hathaway, Tanya ^a   Subtil, Antonio ^a   Kuo, Philip ^a   Foss, Francine ^a,b  

^a Department of Dermatology ^*

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bexarotene; CD25; Corticosteroids; Dexamethasone; T cell lymphoma

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEXAROTENE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; VINCRISTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE CYCLE TREATMENT; PANNICULITIS; PHENOTYPE; PROGNOSIS; SUBCUTANEOUS PANNICULITIS T CELL LYMPHOMA; SYSTEMIC THERAPY; T CELL LYMPHOMA; TREATMENT RESPONSE;

EID: 35748963816     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.040     Document Type: Article

References (22)

1. Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991; 15:17-27.
2. Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American Lymphoma (REAL) classification. Eur J Cancer 2002; 38:75-81.
3. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998; 22:881-893.
4. Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am j Dermatopathol 2001; 23:206-215.
5. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 2005; 153:874-880.
6. Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol 2006; 33(suppl 1):18-26.
7. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97:610-627.
8. Toro JR, Beaty M, Sorbara L, et al. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol 2000; 136:1024-1032.
9. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significandy decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101:3407-3412.
10. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007; 136:439-447.
11. McGinnis KS, Shapiro M, Junkins-Hopkins JM, et al. Denileukin diftitox for the treatment of panniculitic lymphoma. Arch Dermatol 2002; 138:740-742.
12. Au WY, Ng WM, Choy C, et al. Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol 2000; 143:408-410.
13. Hashimoto H, Sawada K, Koizumi K, et al. Effective CD34+ selected autologous peripheral blood stem cell transplantation in a patient with subcutaneous panniculitic T cell lymphoma (SPTCL) transformed into leukemia. Bone Marrow Transplant 1999; 24:1369-1371.
14. Haycox CL, Back AL, Raugi GJ, et al. Subcutaneous T-cell lymphoma treated with systemic chemotherapy, autologous stem cell support, and limb amputation. J Am Acad Dermatol 1997; 37:832-835.
15. Thomson AB, McKenzie KJ, Jackson R, et al. Subcutaneous panniculitic T-cell lymphoma in childhood: successful response to chemotherapy. Med Pediatr Oncol 2001; 37:549-552.
16. Bacha P, Williams DP, Waters C, et al. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167:612-622.
17. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 1:298-302.
18. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-388.
19. Williams DP, Snider CE, Strom TB, et al. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265:11885-11889.
20. Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126:575-583.
21. Jones D, Ibrahim S, Patel K, et al. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin Cancer Res 2004; 10:5587-5594.
22. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005; 106:454-457.